What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

1. Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study.Journal of gynecologic oncology · 2025
   Trial
2. New insights into breast cancer therapy: application and mechanisms of novel targeted nano-formulation.International journal of pharmaceutics: X · 2026
   Review
3. Paclitaxel drives TREM2Nature communications · 2026
   Article
4. Efficacy and safety of nanoparticle albumin‑bound paclitaxel compared with solvent‑based paclitaxel in adjuvant therapy for breast cancer: A retrospective study.Oncology letters · 2024
   Article
5. The role of kinesin family members in hepatobiliary carcinomas: from bench to bedside.Biomarker research · 2024
   Review
6. Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses.Cancers · 2023
   Review
7. Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas.Frontiers in oncology · 2022
   Review
8. Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?Frontiers in immunology · 2022
   Article
9. Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer.Investigational new drugs · 2021
   Article
10. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.Journal for immunotherapy of cancer · 2021
    Article
11. Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study).Therapeutic advances in medical oncology · 2021
    Article
12. Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review.Frontiers in oncology · 2021
    Article
13. Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Metastatic Breast Cancer: A Meta-Analysis.Journal of clinical medicine · 2019
    Article
14. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
15. Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity.Beilstein journal of nanotechnology · 2019
    Article
16. Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells.Beilstein journal of nanotechnology · 2019
    Article
17. Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools.Genes · 2017
    Review
18. Emerging therapies for breast cancer.Journal of hematology & oncology · 2017
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as